Endometrial Cancer Trial Drug Now Free
Women with endometrial cancer will no longer have to pay for a drug being studied in a hormonal therapy clinical trial. Thanks to funding from a $10.4 million Specialized Program of Research Excellence (SPORE) grant, M. D. Anderson study investigators hope to recruit more women in a Phase II clinical trial for Mifepristone as a treatment for specific types of endometrial cancer. Before the SPORE funding became available from the National Cancer Institute, study participants had to pay $500 a month to cover the costs of the drug.The goal of the study is to determine the potential benefit of Mifepristone for recurrent or advanced endometrial cancer patients with tumors that are sensitive to estrogen (progesterone-receptor positive) or patients with low-grade endometrial stromal sarcoma (LGESS), a less common cancer that develops in the supporting connective tissue of the endometrium....(more info via link above).
Details of the Clinical Trial:
Mifepristone for Patients With Endometrial Cancer and LGESS
This study is currently recruiting participants. Verified by M.D. Anderson Cancer Center, July 2007
Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)